Medicare Enrolled
Dr. Nighat Sarwar, M.D.
Neurology · Fresno, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sarwar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sarwar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sarwar
Dr. Nighat Sarwar is a neurology specialist in Fresno, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Sarwar performed 36,214 Medicare services across 1,035 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sarwar received a total of $150,751 from 100 pharmaceutical and/or device companies across 1800 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sarwar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 3% volume in CA
$150,751 industry payments
Medicare Practice Summary
Medicare Utilization ↗36,214
Medicare services
Top 3% in CA for neurology
1,035
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,811 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, eptinezumab-jjmr, 1 mg | 16,400 | $13 | $20 |
| Inclisiran injection (Leqvio) for cholesterol | 9,940 | $9 | $20 |
| Denosumab injection (Prolia/Xgeva) | 7,980 | $18 | $45 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
853 | $94 | $185 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
269 | $50 | $400 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
169 | $10 | $149 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
168 | $16 | $160 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
141 | $124 | $312 |
| Bilateral facial and neck nerve muscle paralysis injection Injection of a chemical agent to paralyze muscles in the face and neck on both sides. |
93 | $113 | $400 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
56 | $136 | $211 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
45 | $142 | $451 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
41 | $108 | $449 |
| New patient office visit, complex (60-74 min) | 25 | $173 | $448 |
| Electromyography of arm or leg muscles A test that measures the electrical activity in the muscles of the arm or leg using a needle electrode. It helps evaluate the health of muscles and the nerve cells that control them. |
19 | $81 | $169 |
| Awake and drowsy EEG A test that records electrical activity in the brain while the patient is awake and drowsy. |
15 | $324 | $800 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.3% high complexity
95.5% medium
3.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$150,751
Total received (2018-2024)
Avg $21,536/year across 7 years
Top 5% in CA for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
100
Companies
1,800
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$97,593 (64.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$29,098 (19.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$24,060 (16.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$12,126
2023
$18,467
2022
$22,745
2021
$15,624
2020
$20,636
2019
$27,550
2018
$33,602
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Biogen, Inc.
$7,127
ACADIA Pharmaceuticals Inc
$479
Novartis Pharmaceuticals Corporation
$379
Celgene Corporation
$300
ABBVIE INC.
$275
Alexion Pharmaceuticals, Inc.
$271
Teva Pharmaceuticals USA, Inc.
$253
AstraZeneca Pharmaceuticals LP
$242
Eisai Inc.
$239
PFIZER INC.
$238
Genentech USA, Inc.
$228
Neurocrine Biosciences, Inc.
$208
Otsuka America Pharmaceutical, Inc.
$199
UCB, Inc.
$197
ARGENX US, INC.
$179
MDD US Operations, LLC
$142
TG Therapeutics, Inc.
$94
Amneal Pharmaceuticals LLC
$88
CATALYST PHARMACEUTICALS, INC.
$83
Lilly USA, LLC
$82
Sumitomo Pharma America, Inc.
$78
GENZYME CORPORATION
$70
Kyowa Kirin, Inc.
$62
SK Life Science, Inc.
$54
Takeda Pharmaceuticals U.S.A., Inc.
$54
BANNER LIFE SCIENCES, LLC
$51
JAZZ PHARMACEUTICALS INC.
$48
Amgen Inc.
$47
Avadel CNS Pharmaceuticals, LLC
$47
HARMONY BIOSCIENCES LLC
$41
Lundbeck LLC
$38
Alnylam Pharmaceuticals Inc.
$37
ANI Pharmaceuticals, Inc.
$31
GE HEALTHCARE
$27
Sandoz Inc.
$26
SCILEX PHARMACEUTICALS INC.
$23
Genentech, Inc.
$21
Azurity Pharmaceuticals, Inc.
$18
Otsuka Pharmaceutical Development & Commercialization, Inc.
$17
Octapharma USA, Inc.
$16
EMD Serono, Inc.
$16
Top 3 companies account for 65.9% of 2024 payments
All-time payments by company (2018-2024) ›
Biogen, Inc.
$101,685
EMD Serono, Inc.
$10,209
Genentech USA, Inc.
$5,820
GENZYME CORPORATION
$5,808
Novartis Pharmaceuticals Corporation
$2,443
Alexion Pharmaceuticals, Inc.
$2,005
Teva Pharmaceuticals USA, Inc.
$1,559
ACADIA Pharmaceuticals Inc
$1,342
UCB, Inc.
$1,140
Genentech, Inc.
$1,081
AbbVie Inc.
$1,025
Sunovion Pharmaceuticals Inc.
$995
ABBVIE INC.
$939
Amgen Inc.
$835
AstraZeneca Pharmaceuticals LP
$770
Celgene Corporation
$643
ARGENX US, INC.
$642
SK Life Science, Inc.
$612
Kyowa Kirin, Inc.
$602
Lilly USA, LLC
$549
Neurocrine Biosciences, Inc.
$544
Amneal Pharmaceuticals LLC
$541
PFIZER INC.
$526
Eisai Inc.
$504
Janssen Pharmaceuticals, Inc
$401
JAZZ PHARMACEUTICALS INC.
$347
Otsuka America Pharmaceutical, Inc.
$327
HARMONY BIOSCIENCES LLC
$307
Avanir Pharmaceuticals, Inc.
$304
Sumitomo Pharma America, Inc.
$290
Almatica Pharma LLC
$273
Lundbeck LLC
$261
Harmony Biosciences LLC
$260
Horizon Therapeutics plc
$255
Mallinckrodt Hospital Products Inc.
$227
IMPEL PHARMACEUTICALS INC.
$224
Merz Pharmaceuticals, LLC
$216
AbbVie, Inc.
$192
MDD US Operations, LLC
$178
LivaNova USA, Inc.
$174
Supernus Pharmaceuticals, Inc.
$171
Mallinckrodt LLC
$170
Acorda Therapeutics, Inc
$155
Alnylam Pharmaceuticals Inc.
$151
Allergan, Inc.
$150
Neurelis, Inc.
$145
BANNER LIFE SCIENCES, LLC
$138
US WorldMeds, LLC
$138
Adamas Pharmaceuticals, Inc.
$122
MITSUBISHI TANABE PHARMA AMERICA, INC.
$117
Biohaven Pharmaceuticals, Inc.
$114
CATALYST PHARMACEUTICALS, INC.
$106
Grifols USA, LLC
$103
Nevro Corp.
$96
TG Therapeutics, Inc.
$94
Takeda Pharmaceuticals U.S.A., Inc.
$93
Banner Life Sciences, LLC
$85
Mallinckrodt Enterprises LLC
$79
Merz North America, Inc.
$76
Biohaven Pharmaceutical Holding Company Ltd.
$75
SANOFI-AVENTIS U.S. LLC
$73
Impax Laboratories, Inc.
$71
EISAI INC.
$69
Octapharma USA, Inc.
$67
TG THERAPEUTICS, INC.
$65
Allergan Inc.
$64
Boston Scientific Corporation
$62
BOSTON SCIENTIFIC CORPORATION
$60
Zogenix Inc.
$57
Avadel CNS Pharmaceuticals, LLC
$47
GE HEALTHCARE
$44
UPSHER-SMITH LABORATORIES LLC
$37
Jazz Pharmaceuticals Inc.
$34
Assertio Therapeutics, Inc.
$32
Azurity Pharmaceuticals, Inc.
$31
ANI Pharmaceuticals, Inc.
$31
Bayer HealthCare Pharmaceuticals Inc.
$29
TerSera Therapeutics LLC
$27
Mylan Specialty L.P.
$27
Sandoz Inc.
$26
Abbott Laboratories
$26
Ipsen Biopharmaceuticals, Inc
$24
ASSERTIO THERAPEUTICS, Inc.
$23
SCILEX PHARMACEUTICALS INC.
$23
GlaxoSmithKline, LLC.
$23
E.R. Squibb & Sons, L.L.C.
$23
Scilex Pharmaceuticals Inc.
$21
Zyla Life Sciences
$20
Avion Pharmaceuticals
$19
Egalet US Inc
$17
Otsuka Pharmaceutical Development & Commercialization, Inc.
$17
Janssen Biotech, Inc.
$16
Tactile Systems Technology Inc
$16
Life Molecular Imaging Ltd
$15
Upsher-Smith Laboratories LLC
$15
Cala Health, Inc.
$14
ARBOR PHARMACEUTICALS, INC.
$14
AngioDynamics, Inc.
$13
GE Healthcare
$12
Merck Sharp & Dohme Corporation
$12
Top 3 companies account for 78.1% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · AFINITOR · AIMOVIG · AJOVY · AMPYRA · AMYVID · ANDEXXA · APOKYN · APTIOM · AUBAGIO · AURYON LASER SYSTEM 100-120 VAC · AUSTEDO · AVONEX · Aimovig · Apokyn · Austedo XR · BAFIERTAM · BOTOX · BRILINTA · BRIUMVI · Betaseron · Briviact · CALA TRIO · CAMBIA · COMIRNATY · COPAXONE · CREXONT · Cambia · DUOPA · DYSPORT · Dhivy · Duopa · ELYXYB - CELECOXIB · EMGALITY · EPIDIOLEX · EVENITY · Enspryng · FASENRA · FIRDAPSE · FYCOMPA · Fintepla · Flexitouch Plus · Fycompa · GENERAL DBS · GILENYA · GLATIRAMER ACETATE · GOCOVRI · GRALISE · Gamunex-C · General - DBS · Gocovri · HORIZANT · HYQVIA · Horizant · INBRIJA · INFLECTRA · INGREZZA · KESIMPTA · KISUNLA · KRYSTEXXA · KYNMOBI · LEMTRADA · LEQEMBI · LUMRYZ · LYRICA · Leqembi · MAVENCLAD · MAYZENT · MS DISEASE STATE · MYOBLOC · Mavenclad · NAMZARIC · NEURACEQ · NORTHERA · NOURIANZ · NUCALA · NUEDEXTA · NUPLAZID · NURTEC ODT · Nayzilam · Neupro · Nourianz · Nuedexta · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONPATTRO · OXTELLAR XR · Ocrevus · Ocrevus Zunovo · Omnia · Ongentys · PANZYGA · PAXLOVID · PIPELINE-MS · PURIFIED CORTROPHIN GEL · Ponvory · Proclaim Family of SCS IPGs · QULIPTA · Quzyttir · RADICAVA · REXULTI · REYVOW · RYTARY · Rebif · Rystiggo · SIMPONI ARIA · SKYCLARYS · SOLIRIS · SPRIX · SUNOSI · Senza · Soliris · TECFIDERA · TOSYMRA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TRINTELLIX · TROKENDI XR · TYSABRI · Trudhesa · Tysabri · UBRELVY · ULTOMIRIS · UPLIZNA · VALTOCO · VNS - Sentiva · VNS THERAPY SENTIVA MODEL 1000 GENERATOR · VNS Therapy · VNS Therapy SenTiva Model 1000 Generator · VRAYLAR · VUMERITY · VYEPTI · VYVGART · VYVGART HYTRULO · Vimpat · WAINUA · WAKIX · Wakix · XCOPRI · XEOMIN · XYREM · XYWAV · Xadago · Xeomin · Xolair · Xyrem · ZEMBRACE SYMTOUCH · ZEPOSIA · ZINPLAVA · ZTLido
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (65%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for neurology in CA.
Geographic Context
Neurologists within 10 mi
33
Per 100K population
3.3
County median income
$71,434
Nearest hospital
SAINT AGNES MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sarwar is a mixed practice specialist, with above-average Medicare volume (top 3% in CA), with speaking/promotional industry engagement in the top 5% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sarwar experienced with injection, eptinezumab-jjmr, 1 mg?
Based on Medicare claims data, Dr. Sarwar performed 16,400 injection, eptinezumab-jjmr, 1 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sarwar receive payments from pharmaceutical companies?
Yes. Dr. Sarwar received a total of $150,751 from 100 companies across 1,800 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sarwar's costs compare to other neurologists in Fresno?
Dr. Sarwar's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sarwar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Fresno
Browse neurologists in Fresno ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in CA
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in CA
Which CA neurologists receive the most from drug and device companies.
By company
Biogen, Inc. Payments to Doctors
See all physicians who received payments from Biogen, Inc.
By company
EMD Serono, Inc. Payments to Doctors
See all physicians who received payments from EMD Serono, Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology